Filing Flows › Co-Diagnostics (CODX) › R&D spending
Co-Diagnostics (CODX) R&D spending by quarter
Co-Diagnostics' R&D spending was $4.2M in Q2 2026 (second quarter 2026), -30% from Q1 2026. Over the last 7 quarters it ranged from $4.2M (Q2 2026) to $5.9M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $4.2M | -30% | -11% |
| Q1 2026 | $5.9M | +16% | +22% |
| Q4 2025 | $5.1M | +14% | +6% |
| Q3 2025 | $4.5M | -4% | — |
| Q2 2025 | $4.7M | -4% | — |
| Q1 2025 | $4.9M | +1% | — |
| Q4 2024 | $4.8M | — | — |
Q2 2026 at a glance
Co-Diagnostics, Q2 2026: revenue $166K (+2% year over year), net loss $6.3M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Co-Diagnostics' R&D spending?
Co-Diagnostics' R&D spending was $4.2M in Q2 2026 (second quarter 2026), -30% from Q1 2026.
How has Co-Diagnostics' R&D spending changed?
Over the last 7 quarters it ranged from $4.2M (Q2 2026) to $5.9M (Q1 2026).